Overview

A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Status:
NOT_YET_RECRUITING

Trial end date:
2026-06-29

Target enrollment:

Participant gender:

Summary

This study has been designed to confirm the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis.

Phase:

PHASE3

Details

Lead Sponsor:

Hansoh BioMedical R&D Company